Pyrovalerone
From Wikipedia, the free encyclopedia
|
Pyrovalerone
|
|
| Systematic (IUPAC) name | |
| 1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C16H23NO |
| Mol. mass | 245.36 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pyrovalerone (Centroton, Thymergix) is a stimulant drug developed in the late 1960s and used in France and some other European countries. It is sometimes prescribed for treating chronic fatigue and lethargy [1] or as an appetite suppressant, though it is used infrequently due to problems with abuse and dependence. [2] Side effects of pyrovalerone include loss of appetite, anxiety, insomnia, and tremor. Withdrawal syndrome following abuse causes depression. [3] Pyrovalerone is a Schedule V drug in the USA. [4] It is closely related to some other stimulant drugs such as prolintane and MDPV.
[edit] Identification
CAS# 1147-62-2 (pyrovalerone hydrochloride); 3563-49-3 (pyrovalerone freebase)
[edit] References
- ^ Gardos G, Cole JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Current Therapeutic Research, Clinical and Experimental. 1971 Oct;13(10):631-5.
- ^ Deniker P, Loo H, Cuche H, Roux JM. Abuse of pyrovalerone by drug addicts. Annales Medico-Psychologiques (Paris) 1975 Nov;2(4):745-8.
- ^ http://www.biam2.org/www/Etr8623.html
- ^ Schedule V Controlled Substances. Retrieved on 2008-01-13.

